Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Type I CRISPR-Cas systems are the most prevalent and versatile among CRISPR-Cas systems, widely distributed across prokaryotes 1 . These systems are composed of multisubunit complexes, known as Cascade (CRISPR-associated complex for antiviral defense), which function by binding to CRISPR RNAs (crRNAs) and targeting complementary DNA sequences for degradation. Type I CRISPR-Cas systems, including subtypes I-A to I-G, have been extensively studied for their potential in genome manipulation [2][3][4][5][6][7][8][9][10][11][12] .Although Type I CRISPR-Cas systems offer significant potential for genome editing and transcriptional regulation, they face notable difficulties when used in eukaryotic cells. The main challenge stems from their considerable size and intricate multi-subunit architecture, which complicate their delivery especially when using viral vectors with strict cargo size limits, such as adeno-associated viruses (AAVs). For example, the Cascade complex of the well-studied Escherichia coli Type I-E CRISPR-Cas3 system consists of five subunits with a total gene size exceeding 4.2 kb 7 . Even the more compact Type I-C Cascade from Neisseria lactamica still comprises four subunits, over 3.2 kb in gene size 13,14 (Figure 1A), which is challenging to package and deliver effectively. Moreover, the assembly of these multiple subunits within cells can be inefficient, leading to reduced activity. Furthermore, the lack of a universal protospacer adjacent motif (PAM) across different Type I CRISPR-Cas systems adds another layer of difficulty, as it limits the range of targetable sequences. These limitations highlight the need for more compact and efficient CRISPR systems, particularly for therapeutic applications that require precise and reliable gene editing.The latest study published in Nature Communications presents a milestone in genome editing and transcriptional regulation within human cells, leveraging the smallest Type I system known to date, the I-F2 subtype 15 . Guo et al. focused on overcoming the limitations of traditional Type I CRISPR-Cas systems by developing a minimal version of the I-F2 subtype, derived from Moraxella osloensis CCUG 350. The I-
Type I CRISPR-Cas systems are the most prevalent and versatile among CRISPR-Cas systems, widely distributed across prokaryotes 1 . These systems are composed of multisubunit complexes, known as Cascade (CRISPR-associated complex for antiviral defense), which function by binding to CRISPR RNAs (crRNAs) and targeting complementary DNA sequences for degradation. Type I CRISPR-Cas systems, including subtypes I-A to I-G, have been extensively studied for their potential in genome manipulation [2][3][4][5][6][7][8][9][10][11][12] .Although Type I CRISPR-Cas systems offer significant potential for genome editing and transcriptional regulation, they face notable difficulties when used in eukaryotic cells. The main challenge stems from their considerable size and intricate multi-subunit architecture, which complicate their delivery especially when using viral vectors with strict cargo size limits, such as adeno-associated viruses (AAVs). For example, the Cascade complex of the well-studied Escherichia coli Type I-E CRISPR-Cas3 system consists of five subunits with a total gene size exceeding 4.2 kb 7 . Even the more compact Type I-C Cascade from Neisseria lactamica still comprises four subunits, over 3.2 kb in gene size 13,14 (Figure 1A), which is challenging to package and deliver effectively. Moreover, the assembly of these multiple subunits within cells can be inefficient, leading to reduced activity. Furthermore, the lack of a universal protospacer adjacent motif (PAM) across different Type I CRISPR-Cas systems adds another layer of difficulty, as it limits the range of targetable sequences. These limitations highlight the need for more compact and efficient CRISPR systems, particularly for therapeutic applications that require precise and reliable gene editing.The latest study published in Nature Communications presents a milestone in genome editing and transcriptional regulation within human cells, leveraging the smallest Type I system known to date, the I-F2 subtype 15 . Guo et al. focused on overcoming the limitations of traditional Type I CRISPR-Cas systems by developing a minimal version of the I-F2 subtype, derived from Moraxella osloensis CCUG 350. The I-
CRISPR-Cas systems function as adaptive immune mechanisms in bacteria and archaea and offer protection against phages and other mobile genetic elements. Among many types of CRISPR-Cas systems, Type I CRISPR-Cas systems are most abundant, with target interference depending on a multi-subunit, RNA-guided complex known as Cascade that recruits a transacting helicase nuclease, Cas3, to degrade the target. While structural studies on several other types of Cas3 have been conducted long ago, it was only recently that the structural study of Type I-C Cas3 in complex with Cascade was revealed, shedding light on how Cas3 achieve its activity in the Cascade complex. In the present study, we elucidated the first structure of standalone Type I-C Cas3 from Neisseria lactamica (NlaCas3). Structural analysis revealed that the histidine–aspartate (HD) nuclease active site of NlaCas3 was bound to two Fe2+ ions that inhibited its activity. Moreover, NlaCas3 could cleave both single-stranded and double-stranded DNA in the presence of Ni2+ or Co2+, showing the highest activity in the presence of both Ni2+ and Mg2+ ions. By comparing the structural studies of various Cas3 proteins, we determined that our NlaCas3 stays in an inactive conformation, allowing us to understand the structural changes associated with its activation and their implication.
The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 system, a groundbreaking innovation in genetic engineering, has revolutionized our approach to surmounting complex diseases, culminating in CASGEVY ™ approved for sickle cell anemia. Derived from a microbial immune defense mechanism, CRISPR/Cas9, characterized as precision, maneuverability and universality in gene editing, has been harnessed as a versatile tool for precisely manipulating DNA in mammals. In the process of applying it to practice, the consecutive exploitation of novel orthologs and variants never ceases. It's conducive to understanding the essentialities of diseases, particularly cancer, which is crucial for diagnosis, prevention, and treatment. CRISPR/Cas9 is used not only to investigate tumorous genes functioning but also to model disparate cancers, providing valuable insights into tumor biology, resistance, and immune evasion. Upon cancer therapy, CRISPR/Cas9 is instrumental in developing individual and precise cancer therapies that can selectively activate or deactivate genes within tumor cells, aiming to cripple tumor growth and invasion and sensitize cancer cells to treatments. Furthermore, it facilitates the development of innovative treatments, enhancing the targeting efficiency of reprogrammed immune cells, exemplified by advancements in CAR-T regimen. Beyond therapy, it is a potent tool for screening susceptible genes, offering the possibility of intervening before the tumor initiative or progresses. However, despite its vast potential, the application of CRISPR/Cas9 in cancer research and therapy is accompanied by significant efficacy, efficiency, technical, and safety considerations. Escalating technology innovations are warranted to address these issues. The CRISPR/Cas9 system is revolutionizing cancer research and treatment, opening up new avenues for advancements in our understanding and management of cancers. The integration of this evolving technology into clinical practice promises a new era of precision oncology, with targeted, personalized, and potentially curative therapies for cancer patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.